279 related articles for article (PubMed ID: 16894075)
1. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Ylitalo N; Brogly S; Hughes MD; Nachman S; Dankner W; Van Dyke R; Seage GR;
Arch Pediatr Adolesc Med; 2006 Aug; 160(8):778-87. PubMed ID: 16894075
[TBL] [Abstract][Full Text] [Related]
2. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
3. Impact of antiretroviral therapy on opportunistic infections of HIV-infected children in the therapeutic research, education and AIDS training asia pediatric HIV observational database.
Prasitsuebsai W; Kariminia A; Puthanakit T; Lumbiganon P; Hansudewechakul R; Siew Moy F; Law M; Kumarasamy N; Razali K; Sirisanthana V; Sohn AH; Chokephaibulkit K
Pediatr Infect Dis J; 2014 Jul; 33(7):747-52. PubMed ID: 24378942
[TBL] [Abstract][Full Text] [Related]
4. Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
Gona P; Van Dyke RB; Williams PL; Dankner WM; Chernoff MC; Nachman SA; Seage GR
JAMA; 2006 Jul; 296(3):292-300. PubMed ID: 16849662
[TBL] [Abstract][Full Text] [Related]
5. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
6. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
[TBL] [Abstract][Full Text] [Related]
7. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
8. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.
Dankner WM; Lindsey JC; Levin MJ;
Pediatr Infect Dis J; 2001 Jan; 20(1):40-8. PubMed ID: 11176565
[TBL] [Abstract][Full Text] [Related]
9. Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children.
Nesheim SR; Hardnett F; Wheeling JT; Siberry GK; Paul ME; Emmanuel P; Bohannon B; Dominguez K;
Pediatr Infect Dis J; 2013 Oct; 32(10):1089-95. PubMed ID: 24067552
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.
Mofenson LM; Brady MT; Danner SP; Dominguez KL; Hazra R; Handelsman E; Havens P; Nesheim S; Read JS; Serchuck L; Van Dyke R; ; ; ; ;
MMWR Recomm Rep; 2009 Sep; 58(RR-11):1-166. PubMed ID: 19730409
[TBL] [Abstract][Full Text] [Related]
11. [Approach to opportunistic illness in the HAART era].
Imamura A
Nihon Rinsho; 2002 Apr; 60(4):757-62. PubMed ID: 11968784
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Dyke RB; Seage GR;
Clin Infect Dis; 2008 Jun; 46(11):1751-60. PubMed ID: 18426371
[TBL] [Abstract][Full Text] [Related]
14. Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.
Oliveira R; Krauss M; Essama-Bibi S; Hofer C; Robert Harris D; Tiraboschi A; de Souza R; Marques H; Succi R; Abreu T; Della Negra M; Hazra R; Mofenson LM; Siberry GK;
Clin Infect Dis; 2010 Dec; 51(11):1325-33. PubMed ID: 21039218
[TBL] [Abstract][Full Text] [Related]
15. Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America.
Wohl AR; Lu S; Turner J; Kovacs A; Witt M; Squires K; Towner W; Beer V
AIDS Patient Care STDS; 2003 Jun; 17(6):267-75. PubMed ID: 12880490
[TBL] [Abstract][Full Text] [Related]
16. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.
Brady MT; Oleske JM; Williams PL; Elgie C; Mofenson LM; Dankner WM; Van Dyke RB;
J Acquir Immune Defic Syndr; 2010 Jan; 53(1):86-94. PubMed ID: 20035164
[TBL] [Abstract][Full Text] [Related]
17. Incidence of common opportunistic infections among HIV-infected children on ART at Debre Markos referral hospital, Northwest Ethiopia: a retrospective cohort study.
Melkamu MW; Gebeyehu MT; Afenigus AD; Hibstie YT; Temesgen B; Petrucka P; Alebel A
BMC Infect Dis; 2020 Jan; 20(1):50. PubMed ID: 31948393
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
19. Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
Kapogiannis BG; Soe MM; Nesheim SR; Abrams EJ; Carter RJ; Farley J; Palumbo P; Koenig LJ; Bulterys M
Clin Infect Dis; 2011 Nov; 53(10):1024-34. PubMed ID: 22002982
[TBL] [Abstract][Full Text] [Related]
20. Short- and Long-term Risks of Highly Active Antiretroviral Treatment with Incident Opportunistic Infections among People Living with HIV/AIDS.
Yen YF; Chen M; Jen IA; Chuang PH; Lee CY; Lin SI; Chen YA
Sci Rep; 2019 Mar; 9(1):3476. PubMed ID: 30837537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
